QQQ $ 584.62 $ -14.20 (-2.37 %)
DIA $ 458.30 $ -3.66 (-0.79 %)
SPY $ 652.19 $ -10.10 (-1.52 %)
TLT $ 89.30 $ 0.35 (0.39 %)
GLD $ 375.00 $ -0.11 (-0.03 %)
$ 17.63
-- x --
-- x --
-- - --
$ 16.04 - $ 22.99
5,847,503
na
4.27B
$ 0.62
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2022 04-03-2022 10-Q
2 03-08-2022 01-02-2022 10-K
3 11-08-2021 10-03-2021 10-Q
4 08-09-2021 07-04-2021 10-Q
5 05-18-2021 04-04-2021 10-Q
6 03-19-2021 01-03-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Quidel Corporation (NASDAQ:QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays a...

 morgan-stanley-maintains-equal-weight-on-ortho-clinical-diagnostic-raises-price-target-to-1819

Morgan Stanley maintains Ortho Clinical Diagnostic (NASDAQ:OCDX) with a Equal-Weight and raises the price target from $16.9 t...

 ortho-clinical-diagnostic-q1-adj-eps-023-beats-020-estimate-sales-49500m-miss-50821m-estimate

Ortho Clinical Diagnostic (NASDAQ:OCDX) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimat...

 earnings-scheduled-for-may-4-2022

  Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per s...

 ortho-clinical-diagnostics-holdings-shares-move-lower-morgan-stanley-downgrades-from-overweight-to-equal-weight

-Reuters

 benzingas-top-ratings-upgrades-downgrades-for-february-17-2022

Upgrades

 ortho-clinical-diagnostics-q4-eps-beat-estimates

Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) 

 evercore-isi-group-upgrades-ortho-clinical-diagnostic-to-outperform-announces-21-price-target

Evercore ISI Group analyst Vijay Kumar upgrades Ortho Clinical Diagnostic (NASDAQ:OCDX) from In-Line to Outperform and annou...

 ortho-clinical-diagnostic-q4-earnings-insights

Ortho Clinical Diagnostic (NASDAQ:OCDX) reported its Q4 earnings results on Wednesday, February 16, 2022 at 04:30 PM. Here'...

 ortho-clinical-diagnostic-q4-eps-018-beats-015-estimate-sales-52100m-miss-52117m-estimate

Ortho Clinical Diagnostic (NASDAQ:OCDX) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimat...

 earnings-scheduled-for-february-16-2022

  Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on reve...

 ortho-clinical-diagnostic-earnings-preview

Ortho Clinical Diagnostic (NASDAQ:OCDX) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here'...

 12-health-care-stocks-moving-in-fridays-after-market-session

Gainers Quidel (NASDAQ:QDEL) shares increased by 7.4% to $106.2 during Friday's after-market session. The market value of ...

 12-health-care-stocks-moving-in-thursdays-after-market-session

Gainers Cidara Therapeutics (NASDAQ:CDTX) stock moved upwards by 14.1% to $0.91 during Thursday's after-market session. Th...

 wholly-owned-subsidiary-shanghai-medconn-biotechnology-and-ortho-biotechnology-development-entered-into-strategic-cooperation-and-joint-venture-agreement

https://ir.orthoclinicaldiagnostics.com/news-releases/news-release-details/wholly-owned-subsidiary-shanghai-medconn-biotechnolo...

 10-biggest-price-target-changes-for-monday

Morgan Stanley cut Foot Locker, Inc. (NYSE: FL) price target from $66 to $47. Foot Locker shares fell 0.1% to $41.90 in pre...

 hc-wainwright--co-downgrades-ortho-clinical-diagnostic-to-neutral-announces-2468-price-target

HC Wainwright & Co. analyst Yi Chen downgrades Ortho Clinical Diagnostic (NASDAQ:OCDX) from Buy to Neutral and announces...

 barclays-downgrades-ortho-clinical-diagnostic-to-equal-weight-lowers-price-target-to-25

Barclays analyst Luke Sergott downgrades Ortho Clinical Diagnostic (NASDAQ:OCDX) from Overweight to Equal-Weight and lowers ...

 evercore-isi-group-downgrades-ortho-clinical-diagnostic-to-in-line

Evercore ISI Group analyst Vijay Kumar downgrades Ortho Clinical Diagnostic (NASDAQ:OCDX) from Outperform to In-Line.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION